We are live on ! Find out more
CC

Commodore Capital Portfolio holdings

AUM $1.73B
1-Year Est. Return 298.96%
This Fund
S&P 500
This Quarter Est. Return
-0.98%
1 Year Est. Return
+298.96%
3 Year Est. Return
+2,048.53%
5 Year Est. Return
+6,668.48%
10 Year Est. Return
–
AUM
$473M
AUM Growth
+$25.3M
Cap. Flow
+$53.8M
Cap. Flow %
11.37%
Top 10 Hldgs %
75.64%
Holding
30
New
3
Increased
11
Reduced
4
Closed
6

Top Buys

Rank Stock Value
1
MRUS
Merus
MRUS
+$16.7M
2
KURA icon
Kura Oncology
KURA
+$15.1M
3
XENE icon
Xenon Pharmaceuticals
XENE
+$11.9M
4
ARWR icon
Arrowhead Research
ARWR
+$11.8M
5
COGT icon
Cogent Biosciences
COGT
+$9.86M

Top Sells

Rank Stock Value
1
CCCC icon
C4 Therapeutics
CCCC
+$11.7M
2
KPTI icon
Karyopharm Therapeutics
KPTI
+$9.94M
3
BLU
BELLUS Health Inc.
BLU
+$9.47M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$7.86M
5
GNCA
Genocea Biosciences, Inc.
GNCA
+$3.85M

Sector Composition

Rank Sector Weight
1 Healthcare 99.48%
2 Financials 0.52%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRUS
1
DELISTED
Merus
MRUS
$59.2M 12.52%
2,615,762
+799,341
+44% +$16.7M
XENE icon
2
Xenon Pharmaceuticals
XENE
$6.32B
$48.5M 10.26%
1,594,932
+392,319
+33% +$11.9M
COGT icon
3
Cogent Biosciences
COGT
$6.79B
$44.6M 9.43%
4,944,708
+1,443,940
+41% +$9.86M
BLU
4
DELISTED
BELLUS Health Inc.
BLU
$41.4M 8.75%
4,479,784
-1,157,846
-21% -$9.47M
CYTK icon
5
Cytokinetics
CYTK
$11B
$35.1M 7.42%
893,646
+38,994
+5% +$1.57M
ACRS icon
6
Aclaris Therapeutics
ACRS
$730M
$33.7M 7.12%
2,410,622
+95,974
+4% +$1.34M
KURA icon
7
Kura Oncology
KURA
$922M
$33.5M 7.08%
1,826,491
+1,049,977
+135% +$15.1M
ISEE
8
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$23.2M 4.9%
2,409,961
+195,000
+9% +$2.45M
TCDA
9
DELISTED
Tricida, Inc. Common Stock
TCDA
$19.6M 4.15%
2,028,453
+283,883
+16% +$2.7M
VRDN icon
10
Viridian Therapeutics
VRDN
$2.13B
$19M 4.01%
1,638,609
+687,270
+72% +$9.24M
CBAY
11
DELISTED
Cymabay Therapeutics
CBAY
$16.9M 3.58%
5,738,500
– –
STSA
12
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
$15.4M 3.25%
3,711,286
– –
CLDX icon
13
Celldex Therapeutics
CLDX
$2.77B
$14.5M 3.07%
538,812
+297,613
+123% +$8.64M
DAWN
14
DELISTED
Day One Biopharmaceuticals
DAWN
$13.2M 2.8%
+739,661
New +$7.64M
VTGN icon
15
VistaGen Therapeutics
VTGN
$9.29M
$11.5M 2.43%
434,969
+98,395
+29% +$3.47M
ARWR icon
16
Arrowhead Research
ARWR
$12.1B
$11M 2.33%
+312,533
New +$11.8M
KPTI icon
17
Karyopharm Therapeutics
KPTI
$168M
$8.73M 1.85%
129,041
-108,362
-46% -$9.94M
CELC icon
18
Celcuity
CELC
$4.03B
$8.38M 1.77%
920,464
– –
RZLT icon
19
Rezolute
RZLT
$480M
$3.91M 0.83%
+1,210,000
New +$4.02M
IMUX icon
20
Immunic
IMUX
$182M
$3.1M 0.66%
89,301
– –
KALV
21
DELISTED
KalVista Pharmaceuticals
KALV
$3.08M 0.65%
312,553
– –
BLSA
22
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$2.48M 0.52%
250,000
– –
TNYA icon
23
Tenaya Therapeutics
TNYA
$168M
$2.01M 0.43%
357,699
-156,231
-30% -$1.26M
IVA
24
Inventiva
IVA
$1.05B
$995K 0.21%
175,500
-87,158
-33% -$792K
CCCC icon
25
C4 Therapeutics
CCCC
$376M
– –
-481,094
Closed -$11.7M
1
2

Similar funds

RIA
Regal Investment Advisors Kentwood, Michigan $1.73B AUM 17.74% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
MCWS
McKinley Carter Wealth Services Wheeling, West Virginia $1.73B AUM 17.28% 1-Year Est. Return
VCA
Verdence Capital Advisors Hunt Valley, Maryland $1.72B AUM 24.88% 1-Year Est. Return
ESBC
E.S. Barr & Co Lexington, Kentucky $1.72B AUM 12.69% 1-Year Est. Return
MSR
Main Street Research Lakeville, Connecticut $1.72B AUM 48.78% 1-Year Est. Return
WJA
Willis Johnson & Associates Houston, Texas $1.72B AUM 16.93% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

Commodore Capital's Q2 2022 Portfolio in Review

As of Q2 2022, Commodore Capital held 30 positions worth $473M, up 5.6% from $448M the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Commodore Capital deployed $53.8M of net new capital in Q2 2022, opening 3 new positions and adding to 11 existing holdings. Its largest new stake was Arrowhead Research: 312,533 shares worth $11M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Karyopharm Therapeutics, an estimated $9.94M trimmed.

  • Commodore Capital's largest Q2 2022 buy was Arrowhead Research: 312,533 shares worth $11M.
  • Commodore Capital added most to Merus in Q2 2022, an estimated $16.7M increase.
  • Commodore Capital's biggest Q2 2022 reduction was Karyopharm Therapeutics, cutting an estimated $9.94M.
  • Commodore Capital fully exited C4 Therapeutics in Q2 2022, selling an estimated $11.7M.
  • Commodore Capital's ten largest holdings make up 76% of its $473M portfolio in Q2 2022.
  • Commodore Capital opened 3 new positions and closed 6 in Q2 2022.
  • Commodore Capital's portfolio value rose 5.6% quarter-over-quarter to $473M.

Based on Commodore Capital's 13F filing for Q2 2022, filed 15 Aug 2022.